347850.KQ D&D PharmaTech Co.
- Market cap
- KRW 1.87T
- P/E
- -
- P/B
- 13.90x
- ROE
- -26.4%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 347850.KQ undervalued?
Graham numberThe Graham number of D&D PharmaTech Co. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
D&D PharmaTech Co. fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-26.4%), below 10%.
ROA 0/1
Return on assets (-11.1%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (80.0%) is above the industry median (4.8%).
Revenue Growth 2/2
Revenue grew 91.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (81.3%), up to 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 0/2
Cash covers 0.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (13.9x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
D&D PharmaTech Co. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About D&D PharmaTech Co.
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases. The company is also involved in the development of TLY…
Full company profileD&D PharmaTech Co. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
D&D PharmaTech Co. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.36B | 611M | 18.7B | 11.4B | 4.30B | 1.58B |
| Gross Profit | 1.36B | 611M | 18.7B | 11.4B | 4.30B | 1.58B |
| Operating Income | -75.7B | -188B | -8.90B | -34.2B | -34.0B | -42.0B |
| EBITDA | - | -147B | 10.3B | -24.2B | -18.9B | -25.0B |
| Net Income | -68.2B | -136B | 3.93B | -28.6B | -23.6B | -35.5B |
| EPS | -1,635 | -13,047 | 377 | -2,708 | -541 | -811 |
| Balance Sheet | ||||||
| Total Assets | 251B | 93.6B | 79.2B | 97.5B | 97.5B | 320B |
| Total Liabilities | 113B | 84.2B | 32.6B | 27.4B | 18.6B | 186B |
| Shareholders' Equity | 132B | 9.44B | 46.6B | 70.1B | 79.5B | 135B |
| Cash & Short-term Investments | 76.0B | 25.5B | 15.6B | 30.0B | 32.9B | 12.3B |
| Cash Flow | ||||||
| Operating Cash Flow | -51.9B | -53.1B | -9.12B | -21.8B | -21.1B | -33.9B |
| Capital Expenditure | 2.22B | 719M | 45.2M | 416M | 64.4M | 0.00 |
| Free Cash Flow | -54.2B | -53.8B | -9.16B | -22.2B | -21.2B | -33.9B |
| Ratios | ||||||
| ROE | -51.6% | -1,441.3% | 8.4% | -40.8% | -29.6% | -26.4% |
| ROA | -27.2% | -145.3% | 5.0% | -29.4% | -24.1% | -11.1% |
| Net Profit Margin | -5,001.4% | -22,285.3% | 21.1% | -250.3% | -548.1% | -2,246.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
D&D PharmaTech Co. dividends
D&D PharmaTech Co. has not paid dividends in the last 5 fiscal years.
Last stock split: 4:1 on Nov 13, 2025.
Who owns D&D PharmaTech Co.
- Insiders 20.06%
- Institutions 11.07%
- Public & others 68.87%
- Shares outstanding 45.8M
- Free float 32.9M
D&D PharmaTech Co. company profile
- Company name
- D&D PharmaTech Co.
- Ticker
- 347850.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25
- Fiscal year end
- December
- Address
- 27, Geumto-ro 80beon-gil,, Seongnam-si, South Korea, 13453
- Phone
- 82 31 8019 7771
- Website
- ddpharmatech.com
About D&D PharmaTech Co.
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications. In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. The company was founded in 2014 and is based in Seongnam-si, South Korea.
D&D PharmaTech Co. management
9- Dr. Seul-ki Lee Ph.D.Founder, Chairman & CEO · born 1977
- Kang Choon Lee Ph.D.Founder
- Mr. Sung Hoon Hong CPACFO & Director · born 1974
- Anna Nesterenko CPAFinance & Accounting and Controller
- Dr. Yen-Huei Lin Ph.D.Chief Technology & Manufacturing Officer
- PyungAh ParkLegal & Administration and Executive Director
- Ms. EunJi Park Ph.D.Head of Research & Development · born 1978
- John Kwag M.Sc.Head of Business Development and Director
- Mr. Sungmook LimHead of Innovation Growth Department & Director · born 1979